A double blinded, placebo-controlled pilot study to examine reduction of CD34+/CD117+/CD133+ lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma [version 3; referees: 2 approved]

A double blinded, placebo-controlled pilot study to examine reduction of CD34+/CD117+/CD133+ lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma [version 3; referees: 2 approved]

We previously described a population of lymphoid progenitor cells (LPCs) in canine B-cell lymphoma defined by retention of the early progenitor markers CD34 and CD117 and “slow proliferation” molecular signatures that persist in the xenotransplantation setting. We examined whether valspodar, a selec...

Full description

Bibliographic Details
Main Authors: Daisuke Ito, Michael Childress, Nicola Mason, Amber Winter, Timothy O’Brien, Michael Henson, Antonella Borgatti, Mitzi Lewellen, Erika Krick, Jane Stewart, Sarah Lahrman, Bartek Rajwa, Milcah C Scott, Davis Seelig, Joseph Koopmeiners, Stephan Ruetz, Jaime Modiano
Format: Article
Language:English
Published: F1000 Research Ltd 2017-04-01
Series:F1000Research
Subjects:
Immunological Biomarkers
Lymphomas & Myelomas
Non-hematopoietic Stem Cells
Online Access:https://f1000research.com/articles/4-42/v3

Internet

https://f1000research.com/articles/4-42/v3

Similar Items